How does HIPEC work?
Even after surgeons remove all of the tumors that they can see, smaller tumors or microscopic clusters of cancer cells inevitably remain. HIPEC allows for treatment of the cancer that is left behind, including malignant cells hiding in areas that may not be accessible to the surgeons.
By placing the chemotherapy directly into the abdomen, doctors can use a higher dosage of the medication. The heat helps as well: Chemotherapy is absorbed more effectively when hot, and malignant cells lack the ability to repair themselves in the face of high heat the way healthy cells can. The combination of heat and chemotherapy creates an especially lethal environment for cancer cells.
Studies are showing that HIPEC with aggressive surgery improves survival in some cancers when compared to traditional intravenous chemotherapy alone.
Which cancers can be treated with HIPEC?
Cancers that show spread only to the abdominal cavity may benefit from HIPEC.
At City of Hope, we currently treat cancers of the
Other cancers that may benefit from this procedure include peritoneal mesothelioma
and some sarcomas.
How do I become a patient?
At City of Hope, our peritoneal surface malignancy team consists of a multidisciplinary group of experts. We are one of the busiest HIPEC centers in Southern California, and continue to push the envelope in treating these difficult cancers. The team will evaluate your case and present options. Not everyone will be a candidate for HIPEC, but other treatments may be available.
Meet Our HIPEC Team
Byrne Lee, M.D.
Chief, Upper GI and Mixed Tumor Surgery Service
Associate Clinical Professor, Division of Surgical Oncology, Department of Surgery
Mark Wakabayashi, M.D., M.P.H.
Chief, Division of Gynecologic Oncology, Department of Surgery
Co-director, Gynecological Oncology/Peritoneal Malignancy Program
Associate Clinical Professor, Department of Surgery
Gynecologic Oncology Surgeon
Marwan G. Fakih, M.D.
Professor, Department of Medical Oncology & Therapeutics Research
Associate Director for Clinical Investigations, Comprehensive Cancer Center
Medical Director, Judy & Bernard Briskin Center for Clinical Research
Co-director, Gastrointestinal Cancer Program
Section Head, GI Medical Oncology
Vincent Chung, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
Director Phase I Program
Joseph Chao, M.D.
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
NURSE PRACTITIONER/ANCILLARY STAFF